{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:52:19Z","timestamp":1792857139915,"version":"4.5.0"},"reference-count":257,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010429","name":"Erasmus MC Vriendenfonds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"DOI":"10.1186\/s41181-026-00446-y","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T06:24:55Z","timestamp":1777184695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Radionuclide-based pharmaceuticals for breast cancer imaging: state of the art"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3848-1917","authenticated-orcid":false,"given":"P.","family":"Para\u00efso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0034-7069","authenticated-orcid":false,"given":"C. H. M.","family":"van Deurzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9736-5318","authenticated-orcid":false,"given":"Y.","family":"Seimbille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,26]]},"reference":[{"key":"446_CR165","unstructured":"99mTc-HPArk2 SPECT\/CT for the Detection of HER2-positive Breast Cancer [Internet]. 2020 [cited 2019 Dec 7]. https:\/\/clinicaltrials.gov\/study\/NCT04267900. Accessed 7 Dec 2019"},{"key":"446_CR2","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.2967\/jnumed.111.094375","volume":"52","author":"K Abiraj","year":"2011","unstructured":"Abiraj K, Mansi R, Tamma ML, Fani M, Forrer F, Nicolas G, et al. Bombesin antagonist- based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med. 2011;52:1970\u20138.","journal-title":"J Nucl Med"},{"key":"446_CR1","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/chem.200902011","volume":"16","author":"K Abiraj","year":"2010","unstructured":"Abiraj K, Mansi R, Tamma ML, Forrer F, Cescato R, Reubi JC, et al. Tetraamine-derived bifunctional chelators for technetium-99m labelling: Synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP-receptor-positive tumours. Chemistry. 2010;16:2115\u201324.","journal-title":"Chemistry"},{"key":"446_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/pharmaceutics13020182","volume":"13","author":"A Abouzayed","year":"2021","unstructured":"Abouzayed A, Rinne SS, Sabahnoo H, S\u00f6rensen J, Chernov V, Tolmachev V, et al. Preclinical evaluation of 99mTc-labeled GRPR antagonists maSSS\/SES-PEG2-RM26 for imaging of prostate cancer. Pharmaceutics. 2021;13:182.","journal-title":"Pharmaceutics"},{"key":"446_CR4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.nucmedbio.2010.02.009","volume":"37","author":"S Ahlgren","year":"2010","unstructured":"Ahlgren S, Andersson K, Tolmachev V. Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a c-terminally engineered cysteine. Nucl Med Biol. 2010;37:539\u201346.","journal-title":"Nucl Med Biol"},{"key":"446_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-018-0420-x","volume":"25","author":"S Ahmadpour","year":"2018","unstructured":"Ahmadpour S, Noaparast Z, Abedi SM, Hosseinimehr SJ. Tc-HYNIC-(tricine\/EDDA)-FROP peptide for MCF-7 breast tumor targeting and imaging. J Biomed Sci. 2018;25:17.","journal-title":"J Biomed Sci"},{"key":"446_CR6","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.2174\/1871520618666180307142027","volume":"18","author":"S Ahmadpour","year":"2018","unstructured":"Ahmadpour S, Noaparast Z, Abedi SM, Hosseinimehr SJ. Tc-(tricine)-HYNIC-Lys-FROP peptide for breast tumor targeting. Anti-Cancer Agents Med Chem. 2018;18:1295\u2013302.","journal-title":"Anti-Cancer Agents Med Chem"},{"key":"446_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153814","volume":"14","author":"D Albano","year":"2022","unstructured":"Albano D, Dondi F, Bertagna F, Treglia G. The role of [68Ga]Ga-Pentixafor PET\/CT or PET\/MRI in lymphoma. Syst Rev Cancers. 2022;14:3814. . https:\/\/doi.org\/10.3390\/cancers14153814","journal-title":"Syst Rev Cancers"},{"key":"446_CR8","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2967\/jnumed.123.266847","volume":"65","author":"R Altena","year":"2024","unstructured":"Altena R, Bur\u00e9n SA, Blomgren A, Karlsson E, Tzortzakakis A, Brun N, et al. Human epidermal growth factor receptor 2 (HER2) PET imaging of HER2-low breast cancer with [(68)Ga]Ga-ABY-025: results from a pilot study. J Nucl Med Off Publ Soc Nucl Med United States. 2024;65:700\u20137. https:\/\/doi.org\/10.2967\/jnumed.123.266847.","journal-title":"J Nucl Med Off Publ Soc Nucl Med United States"},{"key":"446_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2010.33.5232","volume":"30","author":"E Amir","year":"2012","unstructured":"Amir E, Miller N, Geddie W. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012;30:587\u201392.","journal-title":"J Clin Oncol"},{"key":"446_CR82","unstructured":"A Phase I\/IIa Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Whole-body Distribution, Radiation Dosimetry and Anti-tumor Activity of [177Lu]-NeoB Administered in Patients With Advanced Solid Tumors Known to Overexpress Gastrin-releasing Peptide Receptor (GRPR) [Internet]. 2019 [cited 2019 July 24]. Accessed 24 July 2019 https:\/\/clinicaltrials.gov\/study\/NCT03872778"},{"key":"446_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0196-9781(97)00275-1","volume":"19","author":"J Azay","year":"1998","unstructured":"Azay J, Nagain C, Llinares M, Devin C, Fehrentz JA, Bernad N, et al. Comparative study of in vitro and in vivo activities of bombesin pseudopeptide analogs modified on the C-terminal dipeptide fragment. Peptides. 1998;19:57\u201363.","journal-title":"Peptides"},{"key":"446_CR13","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2967\/jnumed.122.264871","volume":"64","author":"P Backhaus","year":"2023","unstructured":"Backhaus P, Burg MC, Asmus I, Pixberg M, B\u00fcther F, Breyholz H-J, et al. Initial results of (68)Ga-FAPI-46 PET\/MRI to assess response to neoadjuvant chemotherapy in breast cancer. J Nucl Med Off Publ Soc Nucl Med United States. 2023;64:717\u201323. https:\/\/doi.org\/10.2967\/jnumed.122.264871.","journal-title":"J Nucl Med Off Publ Soc Nucl Med United States"},{"key":"446_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1148\/radiol.2021204677","volume":"302","author":"P Backhaus","year":"2022","unstructured":"Backhaus P, Burg MC, Roll W, B\u00fcther F, Breyholz H-J, Weigel S, et al. Simultaneous FAPI PET\/MRI targeting the fibroblast-activation protein for breast cancer. Radiology. 2022;302:39\u201347. https:\/\/doi.org\/10.1148\/radiol.2021204677.","journal-title":"Radiology"},{"key":"446_CR11","doi-asserted-by":"publisher","unstructured":"Bajo AM, Schally AV, Krupa M, Hebert F, Groot K, Szepeshazi K. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2\/HER-2 oncoprotein and c-junand c-fosoncogenes. Proc Natl Acad Sci U S A. 2002;99:3836\u201341. https:\/\/doi.org\/10.1073\/pnas.052715299.","DOI":"10.1073\/pnas.052715299"},{"key":"446_CR16","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.2967\/jnumed.120.258814","volume":"62","author":"IL Bakker","year":"2021","unstructured":"Bakker IL, Fr\u00f6berg AC, Busstra MB, Verzijlbergen JF, Konijnenberg M, Leenders G, et al. GRPR antagonist 68Ga-SB3 PET\/CT-imaging of primary prostate cancer in therapy-naive patients. J Nucl Med. 2021;62:1517\u201323.","journal-title":"J Nucl Med"},{"key":"446_CR15","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s11307-018-1185-z","volume":"20","author":"IL Bakker","year":"2018","unstructured":"Bakker IL, Tiel ST, Haeck J, Doeswijk GN, Blois E, Segbers M, et al. In vivo stabilized SB3, an attractive GRPR antagonist, for pre- and intra-operative imaging for prostate cancer. Mol Imaging Biol. 2018;20:973\u201383.","journal-title":"Mol Imaging Biol"},{"key":"446_CR14","first-page":"1501","volume":"31","author":"WH Bakker","year":"1990","unstructured":"Bakker WH, Krenning EP, Breeman WA, Koper JW, Kooij PP, Reubi JC. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals. J Nucl Med Publ Soc Nucl Med. 1990;31:1501\u20139.","journal-title":"J Nucl Med Publ Soc Nucl Med"},{"key":"446_CR17","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","volume":"47","author":"S Ballal","year":"2020","unstructured":"Ballal S, Yadav MP, Bal C, Sahoo RK, Tripathi M. Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur J Nucl Med Mol Imaging. 2020;47:934\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"446_CR18","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20170969","volume":"91","author":"JR Ballinger","year":"2018","unstructured":"Ballinger JR. Theranostics and precision medicine special feature: review article theranostic radiopharmaceuticals: established agents in current use. Br J Radiol. 2018;91:20170969.","journal-title":"Br J Radiol"},{"key":"446_CR19","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1021\/acs.bioconjchem.9b00239","volume":"30","author":"R Bam","year":"2019","unstructured":"Bam R, Laffey M, Nottberg K, Lown PS, Hackel BJ, Wilson KE. Affibody-indocyanine green based contrast agent for photoacoustic and fluorescence molecular imaging of B7\u2013H3 expression in breast cancer. Bioconjug Chem. 2019;30:1677\u201389.","journal-title":"Bioconjug Chem"},{"key":"446_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00259-019-04503-4","volume":"47","author":"L Baratto","year":"2020","unstructured":"Baratto L, Duan H, Laudicella R, Toriihara A, Hatami N, Ferri V. Physiological 68Ga-RM2 uptake in patients with biochemically recurrent prostate cancer: an atlas of semi-quantitative measurements. Eur J Nucl Med Mol Imaging. 2020a;47:115\u201322. https:\/\/doi.org\/10.1007\/s00259-019-04503-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"446_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2967\/JNUMED.119.234971","volume":"61","author":"L Baratto","year":"2020","unstructured":"Baratto L, Duan H, M\u00e4cke H, Iagaru A. Imaging the distribution of gastrin-releasing peptide receptors in cancer. J Nucl Med. 2020b;61:8. https:\/\/doi.org\/10.2967\/JNUMED.119.234971.","journal-title":"J Nucl Med"},{"key":"446_CR22","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1200\/JCO.2003.09.099","volume":"21","author":"VJ Bardou","year":"2003","unstructured":"Bardou VJ, Arpino G, Elledge RM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21:1973\u20139.","journal-title":"J Clin Oncol"},{"key":"446_CR23","doi-asserted-by":"publisher","first-page":"892","DOI":"10.2967\/jnumed.109.073239","volume":"51","author":"RP Baum","year":"2010","unstructured":"Baum RP, Prasad V, Muller D, Schuchardt C, Orlova A, Wennborg A. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med Publ Soc Nucl Med. 2010;51:892\u20137.","journal-title":"J Nucl Med Publ Soc Nucl Med"},{"key":"446_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2967\/jnumed.117.193847","volume":"59","author":"RP Baum","year":"2018","unstructured":"Baum RP, Singh A, Schuchardt C, Kulkarni HR, Klette I, Wiessalla S, et al. 177Lu-3BP-227 for neurotensin receptor 1\u2013targeted therapy of metastatic pancreatic adenocarcinoma: first clinical results. J Nucl Med Soc Nucl Med. 2018;59:809\u201314. . https:\/\/doi.org\/10.2967\/jnumed.117.193847","journal-title":"J Nucl Med Soc Nucl Med"},{"key":"446_CR25","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1053\/j.semnuclmed.2024.01.004","volume":"54","author":"C Baun","year":"2024","unstructured":"Baun C, Naghavi-Behzad M, Hildebrandt MG, Gerke O, Thisgaard H. Gastrin-releasing peptide receptor as a theranostic target in breast cancer: a systematic scoping review. Semin Nucl Med. 2024;54:256\u201369. https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.01.004.","journal-title":"Semin Nucl Med"},{"key":"446_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00259-018-4099-8","volume":"45","author":"F Bensch","year":"2018","unstructured":"Bensch F, Brouwers AH, Lub-de Hooge MN, de Jong JR, vanderVegt, B., Sleijfer, S. 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. Eur J Nucl Med Mol Imaging. 2018;45:6. . https:\/\/doi.org\/10.1007\/s00259-018-4099-8","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"446_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejphar.2013.01.079","volume":"717","author":"F Bensch","year":"2013","unstructured":"Bensch F, Kruchten M, Lamberts LE, Schroder CP, Hospers GA, Brouwers AH, et al. Molecular imaging for monitoring treatment response in breast cancer patients. Eur J Pharmacol. 2013;717:2\u201311.","journal-title":"Eur J Pharmacol"},{"key":"446_CR26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.apradiso.2013.11.011","volume":"87","author":"VPCMM Be","year":"2014","unstructured":"Be VPCMM. Radioactive equilibrium: 99Mo\/99mTc decay characteristics. Appl Radiat Isot. 2014;87:132\u20136.","journal-title":"Appl Radiat Isot"},{"key":"446_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.23736\/S1824-4785.18.03071-6","volume":"62","author":"G Bisi","year":"2018","unstructured":"Bisi G. Imaging in the evaluation of response to treatment in oncology. Q J Nucl Med Mol Imaging. 2018;62:127\u20138.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"446_CR30","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.2967\/jnumed.120.256826","volume":"62","author":"J Boers","year":"2021","unstructured":"Boers J, Loudini N, Brunsch CL, Koza SA, Vries EFJ, Glaudemans AWJM. Value of 18F-FES PET in solving clinical dilemmas in breast cancer patients: a retrospective study. J Nucl Med. 2021;62:1214\u201320. . https:\/\/doi.org\/10.2967\/jnumed.120.256826","journal-title":"J Nucl Med"},{"key":"446_CR31","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/(SICI)1097-0215(19990517)81:4<658::AID-IJC24>3.0.CO;2-P","volume":"81","author":"WAP Breeman","year":"1999","unstructured":"Breeman WAP, Hofland LJ, Jong M, Bernard BF, Srinivasan A, Kwekkeboom DJ, et al. Evaluation of radiolabeled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer. 1999;81:658\u201365.","journal-title":"Int J Cancer"},{"key":"446_CR32","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1021\/jm00002a014","volume":"38","author":"BO Buckman","year":"1995","unstructured":"Buckman BO, Bonasera TA, Kirschbaum KS, Welch MJ, Katzenellenbogen JA. Fluorine-18-labeled progestin 16\u03b1, 17\u03b1-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity. J Med Chem. 1995;38:328\u201337. https:\/\/doi.org\/10.1021\/jm00002a014.","journal-title":"J Med Chem"},{"key":"446_CR33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.clbc.2011.03.018","volume":"11","author":"HA Burris III","year":"2011","unstructured":"Burris HA III, Tibbitts J, Holden SN, Sliwkowski MX, Lewis Phillips GD. Trastuzumab Emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. Clin Breast Cancer. 2011;11:275\u201382. . https:\/\/doi.org\/10.1016\/j.clbc.2011.03.018","journal-title":"Clin Breast Cancer"},{"key":"446_CR35","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.3892\/ijo.6.6.1165","volume":"6","author":"R Cai","year":"1995","unstructured":"Cai R, Qin Y, Ertl T, Schally A. New pseudononapeptide bombesin antagonists with c-terminal LEU-PSI(CH2N)TAC-NH2 show high binding-affinity to bombesin\/GRP receptors on CFPAC-1 human pancreatic-cancer cells. Int J Oncol. 1995;6:1165\u201372. https:\/\/doi.org\/10.3892\/ijo.6.6.1165.","journal-title":"Int J Oncol"},{"key":"446_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2967\/jnumed.119.241232","volume":"61","author":"JFAP Calais","year":"2020","unstructured":"Calais JFAP. The next billion dollar nuclear theranostics target? J Nucl Med. 2020;61:163\u20135.","journal-title":"J Nucl Med"},{"key":"446_CR37","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194\u2013220.","journal-title":"Ann Oncol"},{"key":"446_CR38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.peptides.2015.03.004","volume":"67","author":"G Carlucci","year":"2015","unstructured":"Carlucci G, Kuipers A, Ananias HJK, Paula Faria D, Dierckx RAJO, Helfrich W. GRPR-selective PET imaging of prostate cancer using [18F]-lanthionine-bombesin analogs. Peptides. 2015;67:54.","journal-title":"Peptides"},{"key":"446_CR39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.23736\/S1824-4785.16.02867-3","volume":"63","author":"JA Carrasquillo","year":"2019","unstructured":"Carrasquillo JA, Morris PG, Humm JL, Smith-Jones PM, Beylergil V, Akhurst T, et al. Copper-64 trastuzumab PET imaging: a reproducibility study. Q J Nucl Med Mol Imaging. 2019;63:191\u20138.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"446_CR40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.10.4285","author":"P Carter","year":"1992","unstructured":"Carter P, Presta L, Gorman CM, Ridgway JBB, Henner D, Wong WLT. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992. https:\/\/doi.org\/10.1073\/pnas.89.10.4285.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"446_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/1040-8428(96)00220-X","volume":"24","author":"R Castiglione","year":"1996","unstructured":"Castiglione R, Gozzini L. Bombesin receptor antagonists. Crit Rev Oncol Hematol. 1996;24:117\u201351.","journal-title":"Crit Rev Oncol Hematol"},{"key":"446_CR42","doi-asserted-by":"publisher","first-page":"318","DOI":"10.2967\/jnumed.107.045054","volume":"49","author":"R Cescato","year":"2008","unstructured":"Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med. 2008;49:318\u201326.","journal-title":"J Nucl Med"},{"key":"446_CR43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/ph5010079","volume":"5","author":"AJ Chang","year":"2012","unstructured":"Chang AJ, DeSilva R, Jain S, Lears K, Rogers B, Lapi S. 89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors. Pharmaceuticals Basel. 2012;5:79\u201393. https:\/\/doi.org\/10.3390\/ph5010079.","journal-title":"Pharmaceuticals Basel"},{"key":"446_CR44","first-page":"41","volume":"143","author":"S Chattopadhyay","year":"2019","unstructured":"Chattopadhyay S, Das SS, Barua L, Pal AK, Kumar U. A compact solvent extraction based (99) Mo\/(99)(m) Tc generator for hospital radiopharmacy. Appl Radiat Isot Data Instrum Methods Use Agric Ind Med. 2019;143:41\u20136.","journal-title":"Appl Radiat Isot Data Instrum Methods Use Agric Ind Med."},{"key":"446_CR45","doi-asserted-by":"publisher","unstructured":"Chen H, Zhao L, Pang Y, Shi J, Gao H, Sun Y, et al. 68Ga-MY6349 PET\/CT imaging to assess trop2 expression in multiple types of cancer. J Clin Invest United States; 2024. https:\/\/doi.org\/10.1172\/JCI185408","DOI":"10.1172\/JCI185408"},{"key":"446_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061631","author":"V Chernov","year":"2023","unstructured":"Chernov V, Rybina A, Zelchan R, Medvedeva A, Bragina O, Lushnikova N, et al. Phase I trial of [99mTc]Tc-maSSS-PEG2-RM26, a bombesin analogue antagonistic to gastrin-releasing peptide receptors (GRPRs), for SPECT imaging of GRPR expression in malignant tumors. Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15061631.","journal-title":"Cancers"},{"key":"446_CR47","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.tem.2004.07.004","volume":"15","author":"RB Clarke","year":"2004","unstructured":"Clarke RB, Anderson E, Howell A. Steroid receptors in human breast cancer. Trends Endocrinol Metab. 2004;15:316\u201323. https:\/\/doi.org\/10.1016\/j.tem.2004.07.004.","journal-title":"Trends Endocrinol Metab"},{"key":"446_CR48","doi-asserted-by":"publisher","first-page":"44","DOI":"10.5858\/arpa.2012-0442-RA","volume":"138","author":"KM Cornejo","year":"2014","unstructured":"Cornejo KM, Kandil D, Khan A, Cosar EF. Theranostic and molecular classification of breast cancer. Arch Pathol Lab Med. 2014;138:44\u201356.","journal-title":"Arch Pathol Lab Med"},{"key":"446_CR34","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/annonc\/mdm058","volume":"18","author":"D C","year":"2007","unstructured":"Cornelio DB, Roesler R, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol. 2007;18:1457\u201366. https:\/\/doi.org\/10.1093\/annonc\/mdm058.","journal-title":"Ann Oncol"},{"key":"446_CR49","doi-asserted-by":"publisher","first-page":"5056","DOI":"10.1016\/S0021-9258(18)60678-7","volume":"263","author":"DH Coy","year":"1988","unstructured":"Coy DH, Heinz-Erian P, Jiang NY, Sasaki Y, Taylor J, Moreau JP, et al. Jensen RT Probing peptide backbone function in bombesin: a reduced peptide bond analogue with potent and specific receptor antagonist activity. J Biol Chem. 1988;263:5056\u201360.","journal-title":"J Biol Chem."},{"key":"446_CR50","doi-asserted-by":"publisher","first-page":"752","DOI":"10.2967\/jnumed.114.153023","volume":"56","author":"SU Dalm","year":"2015","unstructured":"Dalm SU, Martens JWM, Sieuwerts AM, van Deurzen CHM, Koelewijn SJ, de Blois E, et al. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer. J Nucl Med. 2015a;56:752\u20137. https:\/\/doi.org\/10.2967\/jnumed.114.153023.","journal-title":"J Nucl Med"},{"key":"446_CR51","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2967\/jnumed.115.160739","volume":"56","author":"SU Dalm","year":"2015","unstructured":"Dalm SU, Sieuwerts AM, Look MP, Melis M, Deurzen CH, Foekens JA, et al. Clinical relevance of targeting the gastrin-releasing peptide receptor, somatostatin receptor 2, or chemokine C-X-C motif receptor 4 in breast cancer for imaging and therapy. J Nucl Med. 2015b;56:1487\u201393.","journal-title":"J Nucl Med"},{"key":"446_CR53","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.ijbiomac.2017.09.059","volume":"107","author":"A De","year":"2018","unstructured":"De A, Kuppusamy G, Karri V. Affibody molecules for molecular imaging and targeted drug delivery in the management of breast cancer. Int J Biol Macromol. 2018;107:906\u201319.","journal-title":"Int J Biol Macromol"},{"key":"446_CR55","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2967\/jnumed.111.098319","volume":"53","author":"F Dehdashti","year":"2012","unstructured":"Dehdashti F, Laforest R, Gao F, Aft R, Dence C, Zhou D, et al. Assessment of progesterone receptors in breast carcinoma by PET with 21\u201318F-Fluoro-16,17-[(R)-(1\u2019-furylmethylidene)Dioxy]-19-Norpregn-4-Ene-3,20-Dione. J Nucl Med off Publ Soc Nucl Med. 2012;53:363\u201370. . https:\/\/doi.org\/10.2967\/jnumed.111.098319","journal-title":"J Nucl Med off Publ Soc Nucl Med"},{"issue":"8","key":"446_CR54","first-page":"1532","volume":"32","author":"F Dehdashti","year":"1991","unstructured":"Dehdashti F, McGuire AH, Brocklin HF, Siegel BA, Andriole DP, Griffeth LK. Assessment of 21-[18F]fluoro-16\u03b1-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J Nucl Med. 1991;32(8):1532\u201315.","journal-title":"J Nucl Med."},{"key":"446_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-20814-9","volume":"12","author":"F Dehdashti","year":"2021","unstructured":"Dehdashti F, Wu N, Ma CX, Naughton MJ, Katzenellenbogen JA, Siegel BA. Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy. Nat Commun. 2021;12:1\u20139. https:\/\/doi.org\/10.1038\/s41467-020-20814-9.","journal-title":"Nat Commun"},{"key":"446_CR52","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/psc.2458","volume":"18","author":"K De","year":"2012","unstructured":"De K, Bhowmik A, Behera A, Banerjee I, Ghosh MK, Misra M. Synthesis, radiolabeling, and preclinical evaluation of a new octreotide analog for somatostatin receptor-positive tumor scintigraphy. J Pept Sci. 2012;18:720\u201330.","journal-title":"J Pept Sci"},{"key":"446_CR57","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.2967\/jnumed.121.263230","volume":"63","author":"ES Delpassand","year":"2022","unstructured":"Delpassand ES, Tworowska I, Esfandiari R, Torgue J, Hurt J, Shafie A, et al. Targeted alpha-emitter therapy with 212Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: First-in-humans dose-escalation clinical trial. J Nucl Med. 2022;63:1326\u201333.","journal-title":"J Nucl Med"},{"key":"446_CR58","doi-asserted-by":"publisher","first-page":"974","DOI":"10.2967\/jnumed.108.060392","volume":"50","author":"EC Dijkers","year":"2009","unstructured":"Dijkers EC, Kosterink JG, Rademaker AP. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2\/neu immunoPET imaging. J Nucl Med. 2009;50:974\u201381.","journal-title":"J Nucl Med"},{"key":"446_CR59","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/clpt.2010.12","volume":"87","author":"EC Dijkers","year":"2010","unstructured":"Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, Jong J. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586\u201392. . https:\/\/doi.org\/10.1038\/clpt.2010.12","journal-title":"Clin Pharmacol Ther"},{"key":"446_CR60","first-page":"346","volume":"61","author":"L Djaileb","year":"2020","unstructured":"Djaileb L, Morgat C, Veldt A, Virgolini I, Cortes F, Demange A, et al. Preliminary diagnostic performance of [68Ga]-NeoBOMB1 in patients with gastrin-releasing peptide receptor-positive breast, prostate, colorectal or lung tumors (Neofind). J Nucl Med. 2020;61:346.","journal-title":"J Nucl Med"},{"key":"446_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004223","volume":"4","author":"S Dupouy","year":"2009","unstructured":"Dupouy S, Viardot-Foucault V, Alifano M, Souaz\u00e9 F, Plu-Bureau G, Chaouat M, et al. The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression. PLoS ONE. 2009;4:e4223.","journal-title":"PLoS ONE"},{"key":"446_CR63","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1471-2407-9-263","volume":"9","author":"RM Eager","year":"2009","unstructured":"Eager RM, Cunningham CC, Senzer NN, Stephenson J, Anthony SP, O\u2019Day SJ, et al. Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma. BMC Cancer. 2009b;9:263.","journal-title":"BMC Cancer"},{"key":"446_CR62","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.clon.2009.04.007","volume":"21","author":"RM Eager","year":"2009","unstructured":"Eager RM, Cunningham CC, Senzer N, Richards DA, Raju RN, Jones B, et al. Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer. Clin Oncol. 2009a;21:464\u201372.","journal-title":"Clin Oncol"},{"key":"446_CR64","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline. Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"issue":"10","key":"446_CR65","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jama.293.10.1245","volume":"293","author":"JG Elmore","year":"2005","unstructured":"Elmore JG. Screening for breast cancer. JAMA. 2005;293(10):1245\u201356.","journal-title":"JAMA"},{"key":"446_CR66","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1016\/j.peptides.2006.01.028","volume":"27","author":"MB Evers","year":"2006","unstructured":"Evers MB. Neurotensin and growth of normal and neoplastic tissues. Neurotensin Roles Mech. 2006;27:2424\u201333. https:\/\/doi.org\/10.1016\/j.peptides.2006.01.028.","journal-title":"Neurotensin Roles Mech"},{"key":"446_CR67","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.steroids.2007.12.025","volume":"73","author":"EJ Filardo","year":"2008","unstructured":"Filardo EJ, Quinn JA, Sabo E. Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transactivation of the epidermal growth factor receptor. Steroids. 2008;73:870\u20133. https:\/\/doi.org\/10.1016\/j.steroids.2007.12.025.","journal-title":"Steroids"},{"key":"446_CR68","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/17434440.2020.1741348","volume":"17","author":"L Filippi","year":"2020","unstructured":"Filippi L, Chiaravalloti A, Schillaci O, Cianni R, Bagni O. Theranostic approaches in nuclear medicine: current status and future prospects. Expert Rev Med Dev. 2020;17:331\u201343.","journal-title":"Expert Rev Med Dev"},{"key":"446_CR69","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2967\/jnumed.112.103465","volume":"53","author":"AM Fowler","year":"2012","unstructured":"Fowler AM, Chan SR, Sharp TL, Fettig NM, Zhou D, Dence CS. Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer. J Nucl Med. 2012;53:1119\u201326. https:\/\/doi.org\/10.2967\/jnumed.112.103465.","journal-title":"J Nucl Med."},{"key":"446_CR70","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0163-7258(84)90043-3","volume":"25","author":"BJ Furr","year":"1984","unstructured":"Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther. 1984;25:127\u2013205.","journal-title":"Pharmacol Ther"},{"key":"446_CR73","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/annonc\/mdv577","volume":"27","author":"G Gebhart","year":"2016","unstructured":"Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann Oncol. 2016;27:619\u201324.","journal-title":"Ann Oncol"},{"key":"446_CR74","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, Azambuja E, DeMichele A. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32:1475\u201395.","journal-title":"Ann Oncol"},{"key":"446_CR72","doi-asserted-by":"publisher","first-page":"6482","DOI":"10.3390\/molecules26216482","volume":"26","author":"S Ge","year":"2021","unstructured":"Ge S, Li J, Yu Y, Chen Z, Yang Y, Zhu L, et al. Review: radionuclide molecular imaging targeting HER2 in breast cancer with a focus on molecular probes into clinical trials and small peptides. Molecules. 2021;26:6482.","journal-title":"Molecules."},{"key":"446_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26216482","author":"S Ge","year":"2021","unstructured":"Ge S, Li J, Yu Y, Chen Z, Yang Y, Zhu L, et al. Review: radionuclide molecular imaging targeting HER2 in breast cancer with a focus on molecular probes into clinical trials and small peptides. Molecules. 2021. https:\/\/doi.org\/10.3390\/molecules26216482.","journal-title":"Molecules"},{"key":"446_CR75","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. 68Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60:386\u201392.","journal-title":"J Nucl Med"},{"key":"446_CR76","doi-asserted-by":"publisher","first-page":"178","DOI":"10.2967\/jnumed.123.266254","volume":"65","author":"O Gondry","year":"2024","unstructured":"Gondry O, Caveliers V, Xavier C, Raes L, Vanhoeij M, Verfaillie G, et al. Phase II trial assessing the repeatability and tumor uptake of [(68)Ga]Ga-HER2 single-domain antibody PET\/CT in patients with breast carcinoma. J Nucl Med. 2024;65:178\u201384. https:\/\/doi.org\/10.2967\/jnumed.123.266254.","journal-title":"J Nucl Med"},{"key":"446_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06903-8","volume":"7","author":"C Gong","year":"2017","unstructured":"Gong C, Yang Z, Sun Y, Zhang J, Zheng C, Wang L. A preliminary study of 18F-FES PET\/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel. Sci Rep. 2017;7:1:10.","journal-title":"Sci Rep"},{"key":"446_CR78","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1524-4741.2006.00366.x","volume":"13","author":"RJ Gonzalez","year":"2007","unstructured":"Gonzalez RJ, Buzdar AU, Fraser Symmans W. Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (Herceptin). Breast J. 2007;13:72\u20135.","journal-title":"Breast J"},{"key":"446_CR79","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2967\/jnumed.114.141242","volume":"55","author":"E Gourni","year":"2014","unstructured":"Gourni E, Mansi R, Jamous M, Waser B, Smerling C, Burian A, et al. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: Examples of 68Ga- and 64Cu-labeled peptides for PET imaging. J Nucl Med. 2014;55:1719\u201325.","journal-title":"J Nucl Med"},{"key":"446_CR80","doi-asserted-by":"publisher","first-page":"129","DOI":"10.23736\/S1824-4785.17.03038-2","volume":"62","author":"S Grimaldi","year":"2018","unstructured":"Grimaldi S, Terroir M, Caramella C. Advances in oncological treatment: limitations of RECIST 1.1 criteria. Q J Nucl Med Mol Imaging. 2018;62:129\u201339.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"446_CR81","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2967\/jnumed.115.157859","volume":"57","author":"D Groheux","year":"2016","unstructured":"Groheux D, Cochet A, Humbert O, Alberini JL, Hindi\u00e9 E, Mankoff D. 18F-FDG PET\/CT for staging and restaging of breast cancer. J Nucl Med. 2016;57:17\u201326.","journal-title":"J Nucl Med"},{"key":"446_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102286","volume":"100","author":"E Hamilton","year":"2021","unstructured":"Hamilton E, Shastry M, Shiller SM, Ren R. Targeting HER2 heterogeneity in breast cancer. Cancer Treat Rev. 2021;100:100. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102286.","journal-title":"Cancer Treat Rev"},{"key":"446_CR84","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5858\/134.7","volume":"134","author":"MEH Hammond","year":"2010","unstructured":"Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134:48. https:\/\/doi.org\/10.5858\/134.7.","journal-title":"Arch Pathol Lab Med"},{"key":"446_CR85","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"446_CR86","doi-asserted-by":"publisher","first-page":"6102","DOI":"10.1038\/sj.onc.1203973","volume":"19","author":"D Harari","year":"2000","unstructured":"Harari D, Yarden Y. Molecular mechanisms underlying ErbB2\/HER2 action in breast cancer. Oncogene. 2000;19:6102\u201314. https:\/\/doi.org\/10.1038\/sj.onc.1203973.","journal-title":"Oncogene"},{"key":"446_CR87","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1021\/jm00111a027","volume":"34","author":"DC Heimbrook","year":"1991","unstructured":"Heimbrook DC, Saari WS, Balishin NL, Fisher TW, Friedman A, Kiefer DM, et al. Gastrin releasing peptide antagonists with improved potency and stability. J Med Chem. 1991;34:2102\u20137.","journal-title":"J Med Chem"},{"key":"446_CR88","doi-asserted-by":"publisher","first-page":"8260","DOI":"10.3390\/molecules15118260","volume":"15","author":"JW Hicks","year":"2010","unstructured":"Hicks JW, VanBrocklin HF, Wilson AA, Houle S, Vasdev N. Radiolabeled small molecule protein kinase inhibitors for imaging with PET or SPECT. Molecules. 2010;15:8260\u201378.","journal-title":"Molecules"},{"key":"446_CR89","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s10549-010-1264-6","volume":"129","author":"JF Hilton","year":"2011","unstructured":"Hilton JF, Amir E, Hopkins S. Acquisition of metastatic tissue from patients with bone metastases from breast cancer. Breast Cancer Res Treat. 2011;129:761\u20135.","journal-title":"Breast Cancer Res Treat"},{"key":"446_CR90","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s00259-020-05045-w","volume":"48","author":"M Hodolic","year":"2021","unstructured":"Hodolic M, Wu W-Y, Zhao Z, Yu F, Virgolini I, Wang F. Safety and tolerability of 68Ga-NT-20.3, a radiopharmaceutical for targeting neurotensin receptors, in patients with pancreatic ductal adenocarcinoma: the first in-human use. Eur J Nucl Med Mol Imaging. 2021;48:1229\u201334. . https:\/\/doi.org\/10.1007\/s00259-020-05045-w","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"446_CR91","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1021\/mp500601z","volume":"12","author":"S Hofmann","year":"2015","unstructured":"Hofmann S, Maschauer S, Kuwert T, Beck-Sickinger AG, Prante O. Synthesis and in vitro and in vivo evaluation of an 18F-labeled neuropeptide Y analogue for imaging of breast cancer by PET. Mol Pharm. 2015;12:1121\u201330. https:\/\/doi.org\/10.1021\/mp500601z.","journal-title":"Mol Pharm"},{"key":"446_CR93","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1210\/endo-103-5-1742","volume":"103","author":"KB Horwitz","year":"1978","unstructured":"Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology. 1978;103:1742\u201351.","journal-title":"Endocrinology"},{"key":"446_CR92","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/0039-128X(75)90027-6","volume":"25","author":"KB Horwitz","year":"1975","unstructured":"Horwitz KB, McGuire WL. Specific progesterone receptors in human breast cancer. Steroids. 1975;25:497\u2013505.","journal-title":"Steroids"},{"key":"446_CR94","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1007\/s00259-025-07460-3","volume":"53","author":"P Hou","year":"2026","unstructured":"Hou P, Lv J, Tan W, Zhong S, Liang S, Li Y, et al. Integrated [(18)F]FAPI-42 PET\/MR improves diagnostic accuracy in breast cancer: comparison with simultaneously acquired breast MRI. Eur J Nucl Med Mol Imaging. 2026;53:1004\u201314. https:\/\/doi.org\/10.1007\/s00259-025-07460-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"446_CR97","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.2967\/jnumed.125.270132","volume":"66","author":"W Huang","year":"2025","unstructured":"Huang W, Li L, Chao F, Yang Q, Mixdorf JC, Engle JW, et al. [64Cu]Cu-NOTA-EV-F(ab\u2019)2 enables same-day immuno-PET imaging of Nectin-4 in triple-negative breast and urothelial bladder cancers. J Nucl Med. 2025b;66:1365\u201371. https:\/\/doi.org\/10.2967\/jnumed.125.270132.","journal-title":"J Nucl Med"},{"key":"446_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrp.2025.102723","author":"W Huang","year":"2025","unstructured":"Huang W, Wang T, Liang Y, Chao F, Yang Q, Barnhart TE, et al. A zirconium-89-labeled antibody-drug conjugate PET probe for noninvasive monitoring of Nectin4 expression in breast cancer and lung cancer. Cell Rep Phys Sci. 2025a. https:\/\/doi.org\/10.1016\/j.xcrp.2025.102723.","journal-title":"Cell Rep Phys Sci"},{"key":"446_CR98","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1007\/s00259-025-07167-5","volume":"52","author":"W Huang","year":"2025","unstructured":"Huang W, Zhang Y, Xiao X, Yang Q, Mixdorf JC, Sun X, et al. ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [(64)Cu]Cu-NOTA-Trodelvy-F(ab\u2019)(2). Eur J Nucl Med Mol Imaging. 2025c;52:3223\u201337. https:\/\/doi.org\/10.1007\/s00259-025-07167-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"446_CR95","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00633-6","volume":"12","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zhu Y, Qi D, Tang C, Zhang W. Trop2-targeted therapy in breast cancer. Biomark Res. 2024;12:82. https:\/\/doi.org\/10.1186\/s40364-024-00633-6.","journal-title":"Biomark Res"},{"key":"446_CR99","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S1536-1632(02)00019-7","volume":"4","author":"EM Jagoda","year":"2002","unstructured":"Jagoda EM, Aloj L, Seidel J, Lang L, Moody TW, Green S, et al. Comparison of an 18F labeled derivative of vasoactive intestinal peptide and 2-deoxy-2-[18F]fluoro-D-glucose in nude mice bearing breast cancer xenografts. Mol Imaging Biol. 2002;4:369\u201379. https:\/\/doi.org\/10.1016\/S1536-1632(02)00019-7.","journal-title":"Mol Imaging Biol"},{"key":"446_CR100","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.nucmedbio.2014.03.014","volume":"41","author":"M Jamous","year":"2014","unstructured":"Jamous M, Tamma ML, Gourni E, Waser B, Reubi JC, Maecke HR, et al. PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonists. Nucl Med Biol. 2014;41:464\u201370.","journal-title":"Nucl Med Biol"},{"key":"446_CR101","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1021\/ml300410d","volume":"4","author":"K Jansen","year":"2013","unstructured":"Jansen K, Heirbaut L, Cheng JD, Joossens J, Ryabtsova O, Cos P, et al. Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold. ACS Med Chem Lett. 2013;4:491\u20136.","journal-title":"ACS Med Chem Lett"},{"key":"446_CR102","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1021\/jm500031w","volume":"57","author":"K Jansen","year":"2014","unstructured":"Jansen K, Heirbaut L, Verkerk R, Cheng JD, Joossens J, Cos P, et al. Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP. J Med Chem. 2014;57:3053\u201374.","journal-title":"J Med Chem"},{"key":"446_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.107.07108","volume":"60","author":"RT Jensen","year":"2008","unstructured":"Jensen RT, Battey JF, Spindel ER, Benya RV. International union of pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev. 2008;60:1\u201342.","journal-title":"Pharmacol Rev"},{"key":"446_CR104","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4048\/jbc.2015.18.1.63","volume":"18","author":"NY Jung","year":"2015","unstructured":"Jung NY, Kim SH, Kim SH, Seo YY, Oh JK, Choi HS, et al. Effectiveness of breast MRI and (18)F-FDG PET\/CT for the preoperative staging of invasive lobular carcinoma versus ductal carcinoma. J Breast Cancer. 2015;18:63\u201372. https:\/\/doi.org\/10.4048\/jbc.2015.18.1.63.","journal-title":"J Breast Cancer"},{"key":"446_CR105","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0959-8049(97)00072-5","volume":"33","author":"A Jungwirth","year":"1997","unstructured":"Jungwirth A, Pinski J, Galvan G, Halmos G, Szepeshazi K, Gai RZ, et al. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer. 1997;33:1141\u20138. https:\/\/doi.org\/10.1016\/S0959-8049(97)00072-5.","journal-title":"Eur J Cancer"},{"key":"446_CR108","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1021\/acs.molpharmaceut.0c00605","volume":"17","author":"A Kaloudi","year":"2020","unstructured":"Kaloudi A, Kanellopoulos P, Radolf T, Chepurny OG, Rouchota M, Loudos G, et al. Tc-DGA1, a promising CCK2R-antagonist-based tracer for tumor diagnosis with single-photon emission computed tomography. Mol Pharm. 2020;17:3116\u201328.","journal-title":"Mol Pharm."},{"key":"446_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22111950","author":"A Kaloudi","year":"2017","unstructured":"Kaloudi A, Lymperis E, Giarika A, Dalm S, Orlandi F, Barbato D, et al. NeoBOMB1, a GRPR-antagonist for breast cancer theragnostics: first results of a preclinical study with [67Ga]NeoBOMB1 in T-47D cells and tumor-bearing mice. Molecules. 2017. https:\/\/doi.org\/10.3390\/molecules22111950.","journal-title":"Molecules"},{"key":"446_CR109","first-page":"8","volume":"36","author":"JA Katzenellenbogen","year":"1995","unstructured":"Katzenellenbogen JA. Designing steroid receptor-based radiotracers to image breast and prostate tumors. J Nucl Med. 1995;36:8\u201313.","journal-title":"J Nucl Med."},{"key":"446_CR110","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.157958","author":"L Kenny","year":"2016","unstructured":"Kenny L. The use of novel PET tracers to image breast cancer biologic processes such as proliferation, DNA damage and repair, and angiogenesis. J Nucl Med. 2016. https:\/\/doi.org\/10.2967\/jnumed.115.157958.","journal-title":"J Nucl Med"},{"key":"446_CR111","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2967\/jnumed.115.162024","volume":"57","author":"M Keyaerts","year":"2016","unstructured":"Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, et al. Phase I study of 68Ga-HER2-nanobody for PET\/CT assessment of HER2 expression in breast carcinoma. J Nucl Med Off Publ Soc Nucl Med United States. 2016;57:27\u201333. . https:\/\/doi.org\/10.2967\/jnumed.115.162024","journal-title":"J Nucl Med Off Publ Soc Nucl Med United States"},{"key":"446_CR112","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/anie.200905008","volume":"49","author":"IU Khan","year":"2010","unstructured":"Khan IU, Zwanziger D, B\u00f6hme I, Javed M, Naseer H, Hyder SW, et al. Breast-cancer diagnosis by neuropeptide Y analogues: from synthesis to clinical application. Angew Chem Int Ed Engl. 2010;49:1155\u20138. https:\/\/doi.org\/10.1002\/anie.200905008.","journal-title":"Angew Chem Int Ed Engl"},{"key":"446_CR106","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.1158\/1078-0432.CCR-12-3490","volume":"19","author":"E K\u00e4hkonen","year":"2013","unstructured":"K\u00e4hkonen E, Jambor I, Kemppainen J, Lehtio K, Gronroos TJ, Kuisma A, et al. In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res. 2013;19:5434\u201343.","journal-title":"Clin Cancer Res"},{"key":"446_CR113","volume":"14","author":"HJ Kim","year":"2019","unstructured":"Kim HJ, Park JY, Lee TS, Song IH, Cho YL, Chae JR. PET imaging of HER2 expression with an 18F-fluoride labeled aptamer. PLoS ONE. 2019;14:0211047.","journal-title":"PLoS ONE"},{"key":"446_CR115","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s12149-021-01616-5","volume":"35","author":"H K\u00f6mek","year":"2021","unstructured":"K\u00f6mek H, Can C, G\u00fczel Y, Oru\u00e7 Z, G\u00fcndo\u011fan C, Yildirim \u00d6A, et al. 68Ga-FAPI-04 PET\/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET\/CT. Ann Nucl Med. 2021;35:744\u201352. . https:\/\/doi.org\/10.1007\/s12149-021-01616-5","journal-title":"Ann Nucl Med"},{"key":"446_CR114","first-page":"692","volume":"38","author":"AC Kole","year":"1997","unstructured":"Kole AC. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C] Tyrosine PET. J Nucl Med. 1997;38:692\u20136.","journal-title":"J Nucl Med"},{"key":"446_CR116","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/(SICI)1097-0142(19981001)83:7<1335::AID-CNCR10>3.0.CO;2-5","volume":"83","author":"M Kopp\u00e1n","year":"1998","unstructured":"Kopp\u00e1n M, Halmos G, Arencibia JM, Lamharzi N, Schally AV. Bombesin\/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma. Cancer. 1998;83:1335\u201343.","journal-title":"Cancer"},{"key":"446_CR118","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s00259-021-05474-1","volume":"49","author":"C Kratochwil","year":"2021","unstructured":"Kratochwil C, Apostolidis L, Rathke H, Apostolidis C, Bicu F, Bruchertseifer F, et al. Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity. Eur J Nucl Med Mol Imaging. 2021;49:54\u201363.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"446_CR117","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. 68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med Publ Soc Nucl Med. 2019;60:801\u20135.","journal-title":"J Nucl Med Publ Soc Nucl Med"},{"key":"446_CR119","first-page":"1045","volume":"10","author":"J Kreutzfeldt","year":"2020","unstructured":"Kreutzfeldt J, Rozeboom B, Dey N, De P. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. Am J Cancer Res. 2020;10:1045\u201367.","journal-title":"Am J Cancer Res"},{"key":"446_CR120","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1470-2045(13)70292-4","volume":"14","author":"M Kruchten","year":"2013","unstructured":"Kruchten M, Vries EG, Brown M, Vries EF, Glaudemans AW, Dierckx RA, et al. PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol. 2013;14:465\u201375.","journal-title":"Lancet Oncol"},{"key":"446_CR121","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1158\/2159-8290.CD-14-0697","volume":"5","author":"M Kruchten","year":"2015","unstructured":"Kruchten M, Vries EG, Glaudemans AW, Lanschot MC, Faassen M, Kema IP, et al. Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer. Cancer Discov. 2015;5:72\u201381.","journal-title":"Cancer Discov"},{"key":"446_CR122","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00259-019-04504-3","volume":"47","author":"J Kurth","year":"2020","unstructured":"Kurth J, Krause BJ, Schwarzenbock SM, Bergner C, Hakenberg OW, Heuschkel M. First-in-human dosimetry of\u2014gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47:123\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"446_CR123","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1080\/19420862.2016.1255389","volume":"9","author":"K Lam","year":"2017","unstructured":"Lam K, Chan C, Reilly RM. Development and preclinical studies of (64)Cu-NOTA-pertuzumab F(ab\u2019)(2) for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET\/CT. Mabs. 2017;9:154\u201364. https:\/\/doi.org\/10.1080\/19420862.2016.1255389.","journal-title":"Mabs"},{"key":"446_CR124","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1677\/ERC-08-0244","volume":"16","author":"C Lanari","year":"2009","unstructured":"Lanari C, Lamb CA, Fabris VT. The MPA mouse breast cancer model: evidence for a role of progesteronereceptors in breast cancer. Endocr Relat Cancer. 2009;16:333\u201350.","journal-title":"Endocr Relat Cancer"},{"key":"446_CR125","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2967\/jnumed.118.220566","volume":"60","author":"T Langbein","year":"2019","unstructured":"Langbein T, Weber WA, Eiber M. Future of theranostics: an outlook on precision oncology in nuclear medicine. J Nucl Med. 2019;60:13\u20139.","journal-title":"J Nucl Med"},{"key":"446_CR126","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1021\/acsomega.8b03293","volume":"4","author":"J Lau","year":"2019","unstructured":"Lau J, Rousseau E, Zhang Z. Positron emission tomography imaging of the gastrin-releasing peptide receptor with a novel bombesin analogue. ACS Omega. 2019;4:1470\u20138. https:\/\/doi.org\/10.1021\/acsomega.8b03293.","journal-title":"ACS Omega"},{"key":"446_CR128","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1021\/bc1001054","volume":"21","author":"JH Lee","year":"2010","unstructured":"Lee JH, Zhou HB, Dence CS. Development of [F-18] fluorine-substituted Tanaproget as a progesterone receptor imaging agent for positron emission tomography. Bioconjug Chem. 2010;21:1096\u2013104.","journal-title":"Bioconjug Chem"},{"key":"446_CR127","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s13139-019-00588-9","volume":"53","author":"WW Lee","year":"2019","unstructured":"Lee WW. Clinical applications of technetium-99m quantitative single-photon emission computed tomography\/computed tomography. Nucl Med Mol Imaging. 2019;53:172\u201381.","journal-title":"Nucl Med Mol Imaging"},{"key":"446_CR129","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y. Identification of human triple-negative breast cancer subtypes and pre-clinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750\u201367.","journal-title":"J Clin Invest"},{"key":"446_CR130","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1053\/j.semnuclmed.2013.02.003","volume":"43","author":"HM Linden","year":"2013","unstructured":"Linden HM, Dehdashti F. Novel methods and tracers for breast cancer imaging. Semin Nucl Med. 2013;43:324\u20139. https:\/\/doi.org\/10.1053\/j.semnuclmed.2013.02.003.","journal-title":"Semin Nucl Med"},{"key":"446_CR132","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1158\/1078-0432.CCR-10-3321","volume":"17","author":"HM Linden","year":"2011","unstructured":"Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res. 2011;17:4799. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-3321.","journal-title":"Clin Cancer Res."},{"key":"446_CR131","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1200\/JCO.2005.04.3810","volume":"24","author":"HM Linden","year":"2006","unstructured":"Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793\u20139.","journal-title":"J Clin Oncol"},{"key":"446_CR133","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Developmentof quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415\u201322.","journal-title":"J Nucl Med"},{"key":"446_CR136","doi-asserted-by":"publisher","unstructured":"Liu C, Gong C, Liu S, Zhang Y, Zhang Y, Xu X, Yuan H, Wang B, Yang Z. FES PET\/CT influences the staging management of patients with newly diagnosed estrogen receptor-positive breast cancer: a retrospective comparative study with 18F-FDG PET\/CT. Oncologist. 2019;24:1277\u201385. https:\/\/doi.org\/10.1634\/theoncologist.2019-0096.","DOI":"10.1634\/theoncologist.2019-0096"},{"key":"446_CR135","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1097\/MNM.0000000000000576","volume":"37","author":"H Liu","year":"2016","unstructured":"Liu H, Chen Y, Wu S, Song F, Zhang H, Tian M. Molecular imaging using PET and SPECT for identification of breast cancer subtypes. Nucl Med Commun. 2016;37:1116\u201324.","journal-title":"Nucl Med Commun"},{"key":"446_CR134","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3892\/ol.2014.2721","volume":"9","author":"L Liu","year":"2015","unstructured":"Liu L, Xu Q, Cheng L, Ma C, Xiao L, Xu D, et al. NPY1R is a novel peripheral blood marker predictive of metastasis and prognosis in breast cancer patients. Oncol Lett. 2015;9:891\u20136. https:\/\/doi.org\/10.3892\/ol.2014.2721.","journal-title":"Oncol Lett"},{"key":"446_CR137","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1034\/j.1399-3011.1999.00028.x","volume":"53","author":"M Llinares","year":"1999","unstructured":"Llinares M, Devin C, Chaloin O, Azay J, Noel-Artis AM, Bernad N, et al. Syntheses and biological activities of potent bombesin receptor antagonists. J Pept Res. 1999;53:275\u201383.","journal-title":"J Pept Res"},{"key":"446_CR139","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","volume":"60","author":"A Loktev","year":"2019","unstructured":"Loktev A, Lindner T, Burger E-M, Altmann A, Giesel F, Kratochwil C, et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J Nucl Med Publ Soc Nucl Med. 2019;60:1421\u20139.","journal-title":"J Nucl Med Publ Soc Nucl Med"},{"key":"446_CR138","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","volume":"59","author":"A Loktev","year":"2018","unstructured":"Loktev A, Lindner T, Mier W, Debus J, Altmann A, J\u00e4ger D, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59:1423. https:\/\/doi.org\/10.2967\/jnumed.118.210435.","journal-title":"J Nucl Med"},{"key":"446_CR140","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1021\/acs.bioconjchem.8b00225","volume":"29","author":"E Lymperis","year":"2018","unstructured":"Lymperis E, Kaloudi A, Sallegger W, Bakker IL, Krenning EP, Jong M, et al. Radiometal-dependent biological profile of the radiolabeled gastrin-releasing peptide receptor antagonist SB3 in cancer theranostics: Metabolic and biodistribution patterns defined by neprilysin. Bioconjug Chem. 2018;29:1774\u201384.","journal-title":"Bioconjug Chem"},{"key":"446_CR142","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1007\/s00259-015-3232-1","volume":"43","author":"T Maina","year":"2016","unstructured":"Maina T, Bergsma H, Kulkarni HR, Mueller D, Charalambidis D, Krenning EP, et al. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET\/CT. Eur J Nucl Med Mol Imaging. 2016;43:964\u201373.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"446_CR141","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cpet.2016.12.002","volume":"12","author":"T Maina","year":"2017","unstructured":"Maina T, Nock BA. From bench to bed: new gastrin-releasing peptide receptor-directed radioligands and their use in prostate cancer. PET Clin. 2017;12:205\u201317.","journal-title":"PET Clin"},{"key":"446_CR143","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.cpet.2017.02.007","volume":"12","author":"T Maina","year":"2017","unstructured":"Maina T, Nock BA, Kulkarni H, Singh A, Baum RP. Theranostic prospects of gastrin-releasing peptide receptor-radioantagonists in oncology. PET Clin. 2017;12:297\u2013309.","journal-title":"PET Clin"},{"key":"446_CR144","doi-asserted-by":"publisher","first-page":"001","DOI":"10.29328\/journal.hjcsr.1001001","volume":"1","author":"L Mango","year":"2017","unstructured":"Mango L. Theranostics: a unique concept to nuclear medicine. Arch Cancer Sci. 2017;1:001\u20134.","journal-title":"Arch Cancer Sci"},{"issue":"2","key":"446_CR145","first-page":"221","volume":"65","author":"D Mankoff","year":"2023","unstructured":"Mankoff D, Balogova S, Dunnwald L, Dehdashti F, DeVries E, Evangelista L, et al. SNMMI procedure standard\/EANM practice guideline for estrogen receptor imaging of patients with breast cancer using 16\u03b1-[18F] Fluoro-17\u03b2-estradiol PET. SNMMI. 2023;65(2):221\u20133.","journal-title":"SNMMI"},{"key":"446_CR146","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2967\/jnumed.123.266938","volume":"65","author":"D Mankoff","year":"2024","unstructured":"Mankoff D, Balogov\u00e1 S, Dunnwald L, Dehdashti F, DeVries E, Evangelista L, et al. Summary: SNMMI procedure standard\/EANM practice guideline for estrogen receptor imaging of patients with breast cancer using 16\u03b1-[18F]Fluoro-17\u03b2-estradiol PET. J Nucl Med Soc Nucl Med. 2024;65:221\u20133. . https:\/\/doi.org\/10.2967\/jnumed.123.266938","journal-title":"J Nucl Med Soc Nucl Med"},{"key":"446_CR148","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225766","author":"R Mansi","year":"2021","unstructured":"Mansi R, Nock BA, Dalm SU, Busstra MB, Weerden WM, Maina T. Radiolabeled bombesin analogs. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13225766.","journal-title":"Cancers"},{"key":"446_CR147","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00259-010-1596-9","volume":"38","author":"R Mansi","year":"2011","unstructured":"Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPR-positive tumours. Eur J Nucl Med Mol Imaging. 2011;38:97\u2013107.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"446_CR149","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1007\/s00259-008-0814-1","volume":"35","author":"G Mariani","year":"2008","unstructured":"Mariani G, Bruselli L, Duatti A. Is PET always an advantage versus planar and SPECT imaging? Eur J Nucl Med Mol Imaging. 2008;35:1560\u20135.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"446_CR150","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1021\/jm301692p","volume":"56","author":"PJ Marsouvanidis","year":"2013","unstructured":"Marsouvanidis PJ, Nock BA, Hajjaj B, Fehrentz JA, Brunel L, M\u2019Kadmi C, et al. Gastrin releasing peptide receptor-directed radioligands based on a bombesin antagonist: Synthesis, 111In-labeling, and preclinical profile. J Med Chem. 2013;56:2374\u201384.","journal-title":"J Med Chem"},{"key":"446_CR151","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10549-012-2289-9","volume":"136","author":"H Masuda","year":"2012","unstructured":"Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012;136:331\u201345.","journal-title":"Breast Cancer Res Treat"},{"key":"446_CR152","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/0969-8051(96)00068-6","volume":"23","author":"JG McAfee","year":"1996","unstructured":"McAfee JG, Neumann RD. Radiolabeled peptides and other ligands for receptors overexpressed in tumor cells for imaging neoplasms. Nucl Med Biol. 1996;23:673\u20136.","journal-title":"Nucl Med Biol"},{"key":"446_CR153","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.3390\/molecules20022081","volume":"20","author":"R Meletta","year":"2015","unstructured":"Meletta R, M\u00fcller Herde A, Chiotellis A, Isa M, Rancic Z, Borel N, et al. Evaluation of the radiolabeled boronic acid-based FAP inhibitor MIP-1232 for atherosclerotic plaque imaging. Molecules. 2015;20:2081\u201399.","journal-title":"Molecules"},{"key":"446_CR154","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2967\/jnumed.119.236786","volume":"61","author":"C Meyer","year":"2020","unstructured":"Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, et al. Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med Publ Soc Nucl Med. 2020;61:1171\u20137.","journal-title":"J Nucl Med Publ Soc Nucl Med"},{"key":"446_CR155","doi-asserted-by":"publisher","first-page":"262","DOI":"10.2967\/jnumed.125.270411","volume":"67","author":"ES Mittra","year":"2026","unstructured":"Mittra ES, Solnes LB, VanderVeldt AAM, Wong J, Aloj L, Heinrich MC, et al. Phase 1 study of [(177)Lu]Lu-NeoB in patients with advanced solid tumors overexpressing gastrin-releasing peptide receptor: preliminary safety and dosimetry results. J Nucl Med Off Publ Soc Nucl Med United States. 2026;67:262\u20138. https:\/\/doi.org\/10.2967\/jnumed.125.270411.","journal-title":"J Nucl Med Off Publ Soc Nucl Med United States"},{"key":"446_CR156","doi-asserted-by":"publisher","DOI":"10.2147\/bctt.s176070","author":"Z Momenimovahed","year":"2019","unstructured":"Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Auckl). 2019. https:\/\/doi.org\/10.2147\/bctt.s176070.","journal-title":"Breast Cancer (Auckl)"},{"key":"446_CR158","first-page":"476","volume":"11","author":"ES Moon","year":"2021","unstructured":"Moon ES, Ballal S, Yadav MP, Bal C, Van Rymenant Y, Stephan S, et al. Fibroblast activation protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time. Am J Nucl Med Mol Imaging. 2021;11:476\u201391.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"446_CR157","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s41181-020-00102-z","volume":"5","author":"ES Moon","year":"2020","unstructured":"Moon ES, Elvas F, Vliegen G, Lombaerde S, Vangestel C, Bruycker S, et al. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators. EJNMMI Radiopharm Chem. 2020;5:19.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"446_CR159","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1517\/14728222.2016.1164694","volume":"20","author":"P Moreno","year":"2016","unstructured":"Moreno P, Ramos-Alvarez I, Moody TW, Jensen RT. Bombesin related peptides\/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment. Expert Opin Ther Targets. 2016;20:1055\u201373.","journal-title":"Expert Opin Ther Targets"},{"key":"446_CR160","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2967\/jnumed.114.142000","volume":"55","author":"C Morgat","year":"2014","unstructured":"Morgat C, Mishra AK, Varshney R, Allard M, Fernandez P, Hindi\u00e9 E. Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors. J Nucl Med. 2014;55:1650\u20137. https:\/\/doi.org\/10.2967\/jnumed.114.142000.","journal-title":"J Nucl Med"},{"key":"446_CR161","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210905","volume":"14","author":"C Morgat","year":"2019","unstructured":"Morgat C, Schollhammer R, Macgrogan G, Barthe N, Velasco V, Vimont D. Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples. PLoS ONE. 2019;14:0210905.","journal-title":"PLoS ONE"},{"key":"446_CR162","doi-asserted-by":"publisher","unstructured":"Mortimer JE, Bading C JR, C DM, F PS, C PH, M I. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using 64Cu-DOTA-trastuzumab PET. J Nucl Med. 2014;55:23\u20139. https:\/\/doi.org\/10.2967\/jnumed.113.122630","DOI":"10.2967\/jnumed.113.122630"},{"key":"446_CR163","first-page":"1750","volume":"40","author":"M Namer","year":"1980","unstructured":"Namer M, Lalanne C, Baulieu EE. Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer. Cancer Res. 1980;40:1750\u20132.","journal-title":"Cancer Res"},{"key":"446_CR164","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.4161\/cbt.6.11.4874","volume":"6","author":"K Narra","year":"2007","unstructured":"Narra K, Mullins SR, Lee H-O, Strzemkowski-Brun B, Magalong K, Christiansen VJ, et al. Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer. Cancer Biol Ther. 2007;6:1691\u20139.","journal-title":"Cancer Biol Ther"},{"key":"446_CR166","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10549-009-0501-3","volume":"121","author":"R Natrajan","year":"2010","unstructured":"Natrajan R, Weigelt B, Mackay A. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat. 2010;121:575\u201389.","journal-title":"Breast Cancer Res Treat"},{"key":"446_CR168","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1200\/JCO.2010.33.8889","volume":"30","author":"N Niikura","year":"2012","unstructured":"Niikura N, Liu J, Hayashi N. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012b;30:593\u20139.","journal-title":"J Clin Oncol"},{"key":"446_CR167","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1002\/cncr.26512","volume":"118","author":"N Niikura","year":"2012","unstructured":"Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN, et al. Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases. Cancer. 2012a;118:2039\u201347. https:\/\/doi.org\/10.1002\/cncr.26512.","journal-title":"Cancer"},{"key":"446_CR171","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1021\/acs.jmedchem.8b00177","volume":"61","author":"BA Nock","year":"2018","unstructured":"Nock BA, Charalambidis D, Sallegger W, Waser B, Mansi R, Nicolas GP, et al. New gastrin releasing peptide receptor-directed [99mTc] Demobesin 1 mimics: synthesis and comparative evaluation. J Med Chem. 2018;61:3138\u201350.","journal-title":"J Med Chem"},{"key":"446_CR170","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2967\/jnumed.116.178889","volume":"58","author":"BA Nock","year":"2017","unstructured":"Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, et al. Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: Preclinical and first clinical results. J Nucl Med. 2017;58:75\u201380.","journal-title":"J Nucl Med"},{"key":"446_CR172","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205093","volume":"13","author":"B Nock","year":"2021","unstructured":"Nock B, Kaloudi A, Kanellopoulos P, Janota B, Bromi\u0144ska B, Izycki D, et al. [99mTc]Tc-DB15 in GRPR-targeted tumor imaging with SPECT: from preclinical evaluation to the first clinical outcomes. Cancers. 2021;13:5093. . https:\/\/doi.org\/10.3390\/cancers13205093","journal-title":"Cancers"},{"key":"446_CR169","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00259-002-1040-x","volume":"30","author":"B Nock","year":"2003","unstructured":"Nock B, Nikolopoulou A, Chiotellis E, Loudos G, Maintas D, Reubi JC, et al. Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging. 2003;30:247\u201358.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"446_CR173","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1148\/radiol.2016142043","volume":"280","author":"JH O","year":"2016","unstructured":"O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280:576\u201384.","journal-title":"Radiology"},{"key":"446_CR174","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1097\/00006231-199912000-00002","volume":"20","author":"SM Okarvi","year":"1999","unstructured":"Okarvi SM. Recent developments in 99Tcm-labelled peptide-based radiopharmaceuticals: an overview. Nucl Med Commun. 1999;20:1093\u2013112.","journal-title":"Nucl Med Commun"},{"key":"446_CR175","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev.med.56.062804.103324","volume":"56","author":"C Osborne","year":"2005","unstructured":"Osborne C, Tripathy D. Aromatase inhibitors: rationale and use in breast cancer. Annu Rev Med. 2005;56:103\u201316.","journal-title":"Annu Rev Med"},{"key":"446_CR176","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1158\/1078-0432.CCR-07-5211","volume":"14","author":"E Ostermann","year":"2008","unstructured":"Ostermann E, Garin-Chesa P, Heider KH, Kalat M, Lamche H, Puri C, et al. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res. 2008;14:4584\u201392.","journal-title":"Clin Cancer Res"},{"key":"446_CR177","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/jlcr.3531","volume":"60","author":"D Papagiannopoulou","year":"2017","unstructured":"Papagiannopoulou D. Technetium-99m radiochemistry for pharmaceutical applications. J Label Compd Radiopharm. 2017;60:502\u201320.","journal-title":"J Label Compd Radiopharm"},{"key":"446_CR178","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2967\/jnumed.117.194654","volume":"59","author":"M Paquette","year":"2018","unstructured":"Paquette M, Lavall\u00e9e \u00c9, Phoenix S, Ouellet R, Senta H, van Lier JE, et al. Improved estrogen receptor assessment by PET using the novel radiotracer 18F\u20134FMFES in estrogen receptor\u2013positive breast cancer patients: an ongoing phase II Clinical trial. J Nucl Med Soc Nucl Med. 2018;59:197\u2013203. . https:\/\/doi.org\/10.2967\/jnumed.117.194654","journal-title":"J Nucl Med Soc Nucl Med"},{"key":"446_CR179","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bbcan.2006.01.003","volume":"1766","author":"O Patel","year":"2006","unstructured":"Patel O, Shulkes A, Baldwin GS. Gastrin-releasing peptide and cancer. Biochim Biophys Acta Rev Cancer. 2006;1766:41. https:\/\/doi.org\/10.1016\/j.bbcan.2006.01.003.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"446_CR180","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, Rijn M, Jeffrey SS, Rees CA. Molecular portraits of human breast tumours. Nature. 2000;406:747\u201352.","journal-title":"Nature"},{"key":"446_CR181","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0022-3565(24)38013-9","volume":"288","author":"MH Perrin","year":"1999","unstructured":"Perrin MH, Sutton SW, Cervini LA, Rivier JE, Vale WW. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. J Pharmacol Exp Ther. 1999;288:729\u201334.","journal-title":"J Pharmacol Exp Ther"},{"key":"446_CR182","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-013-0699-7","volume":"16","author":"LM Peterson","year":"2014","unstructured":"Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM. A phase 2 study of 16\u03b1-[18F]-fluoro-17\u03b2-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC. Mol Imaging Biol. 2014;16:431:40. https:\/\/doi.org\/10.1007\/s11307-013-0699-7.","journal-title":"Mol Imaging Biol"},{"key":"446_CR183","first-page":"461","volume":"9","author":"R Piva","year":"2017","unstructured":"Piva R, Ticconi F, Ceriani V, Scalorbi F, Fiz F, Capitanio S. Comparative diagnostic accuracy of 18F-FDG PET\/CT for breast cancer recurrence. Breast Cancer Dove Medical Press. 2017;9:461\u201371.","journal-title":"Breast Cancer Dove Medical Press"},{"key":"446_CR184","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1021\/jm400351a","volume":"56","author":"SE Poplawski","year":"2013","unstructured":"Poplawski SE, Lai JH, Li Y, Jin Z, Liu Y, Wu W, et al. Identification of selective and potent inhibitors of fibroblast activation protein and Prolyl Oligopeptidase. J Med Chem. 2013;56:3467\u201377. https:\/\/doi.org\/10.1021\/jm400351a.","journal-title":"J Med Chem"},{"key":"446_CR185","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.bmc.2015.02.009","volume":"23","author":"M Pourghiasian","year":"2015","unstructured":"Pourghiasian M, Liu Z, Pan J, Zhang Z, Colpo N, Lin KS. 18F-AmBF3-MJ9: a novel radiofluorinated bombesin derivative for prostate cancer imaging. Bioorg Med Chem. 2015;23:1500\u20136. . https:\/\/doi.org\/10.1016\/j.bmc.2015.02.009","journal-title":"Bioorg Med Chem"},{"key":"446_CR186","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.22381","volume":"109","author":"EA Rakha","year":"2007","unstructured":"Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25\u201332.","journal-title":"Cancer"},{"key":"446_CR187","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/path.2004","volume":"209","author":"JS Reis-Filho","year":"2006","unstructured":"Reis-Filho JS, Pinheiro C, Lambros MB, Milanezi F, Carvalho S, Savage K. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol. 2006;209:445\u201353.","journal-title":"J Pathol"},{"key":"446_CR190","first-page":"4636","volume":"61","author":"JC Reubi","year":"2001","unstructured":"Reubi JC, Gugger M, Waser B, Schaer J-C. Y1-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res. 2001;61:4636\u201341.","journal-title":"Cancer Res"},{"key":"446_CR188","first-page":"1846","volume":"36","author":"JC Reubi","year":"1995","unstructured":"Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med Soc Nucl Med. 1995;36:1846\u201353.","journal-title":"J Nucl Med Soc Nucl Med"},{"key":"446_CR189","first-page":"3105","volume":"60","author":"JC Reubi","year":"2000","unstructured":"Reubi JC, L\u00e4derach U, Waser B, Gebbers J-O, Robberecht P, Laissue JA. Vasoactive intestinal peptide\/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of Origin1. Cancer Res. 2000;60:3105\u201312.","journal-title":"Cancer Res"},{"key":"446_CR191","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2967\/jnumed.112.114082","volume":"54","author":"A Roivainen","year":"2013","unstructured":"Roivainen A, K\u00e4hkonen E, Luoto P, Borkowski S, Hofmann B, Jambor I, et al. Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013;54:867\u201372.","journal-title":"J Nucl Med"},{"key":"446_CR192","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","volume":"14","author":"JS Ross","year":"2009","unstructured":"Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized therapy. Oncologist. 2009;14:320.","journal-title":"Oncologist"},{"key":"446_CR193","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1002\/jlcr.3815","volume":"1","author":"E Rousseau","year":"2019","unstructured":"Rousseau E, Lau J, Zhang Z. Comparison of biological properties of [ 177Lu]Lu-ProBOMB1 and [ 177 Lu]Lu-NeoBOMB1 for GRPR-targeting. J Label Compd Radiopharm. 2019;1:0\u20132. . https:\/\/doi.org\/10.1002\/jlcr.3815","journal-title":"J Label Compd Radiopharm"},{"key":"446_CR194","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1007\/s00259-022-05926-2","volume":"49","author":"EAM Ruigrok","year":"2022","unstructured":"Ruigrok EAM, Verhoeven M, Konijnenberg MW, de Blois E, de Ridder CMA, Stuurman DC, et al. Safety of [(177)Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity. Eur J Nucl Med Mol Imaging. 2022;49:4440\u201351. https:\/\/doi.org\/10.1007\/s00259-022-05926-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"446_CR195","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235936","author":"E Sakach","year":"2022","unstructured":"Sakach E, Sacks R, Kalinsky K. Trop-2 as a therapeutic target in breast cancer. Cancers Basel. 2022. https:\/\/doi.org\/10.3390\/cancers14235936.","journal-title":"Cancers Basel"},{"key":"446_CR196","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00259-019-04553-8","volume":"47","author":"PY Sala\u00fcn","year":"2020","unstructured":"Sala\u00fcn PY, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M. Good clinical practice recommendations for the use of PET\/CT in oncology. Eur J Nucl Med Mol Imaging. 2020;47:50.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"446_CR197","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1210\/edrv-11-2-221","volume":"11","author":"RJ Santen","year":"1990","unstructured":"Santen RJ, Manni A, Harvey H. Endocrine treatment of breast cancer in women. Endocr Rev. 1990;11:221\u201365.","journal-title":"Endocr Rev"},{"key":"446_CR198","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1007\/s00259-017-3781-6","volume":"44","author":"S Sasada","year":"2017","unstructured":"Sasada S, Kurihara H, Kinoshita T, Yoshida M, Honda N, Shimoi T, et al. Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET. Eur J Nucl Med Mol Imaging. 2017;44:2146\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"446_CR199","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/030089160208800331","volume":"88","author":"F Scopinaro","year":"2002","unstructured":"Scopinaro F, Varvarigou A, Ussof W, Vincentis G, Archimandritis S, Evangelatos G. Breast cancer takes up 99mTc bombesin. Prelim Rep Tumori. 2002;88:25\u20138.","journal-title":"Prelim Rep Tumori"},{"key":"446_CR200","first-page":"1639","volume":"9","author":"AM Scott","year":"2003","unstructured":"Scott AM, Wiseman G, Welt S, Adjei A, Lee F-T, Hopkins W, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res J Am Assoc Cancer Res. 2003;9:1639\u201347.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"446_CR201","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/s0039-128x(02)00025-9","volume":"67","author":"Y Seimbille","year":"2002","unstructured":"Seimbille Y, Rousseau J, B\u00e9nard F, Morin C, Ali H, Avvakumov G, et al. 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids. 2002;67:765\u201375. https:\/\/doi.org\/10.1016\/s0039-128x(02)00025-9.","journal-title":"Steroids"},{"key":"446_CR202","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2174\/138920111795164039","volume":"12","author":"TV Sekar","year":"2011","unstructured":"Sekar TV, Dhanabalan A, Paulmurugan R. Imaging cellular receptors in breast cancers: an overview. Curr Pharm Biotechnol. 2011;12:27. https:\/\/doi.org\/10.2174\/138920111795164039.","journal-title":"Curr Pharm Biotechnol"},{"key":"446_CR203","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03865-y","volume":"21","author":"J Shi","year":"2023","unstructured":"Shi J, Du S, Wang R, Gao H, Luo Q, Hou G, et al. Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer 99mTc-HP-Ark2: a pilot study. J Transl Med. 2023;21:19. https:\/\/doi.org\/10.1186\/s12967-022-03865-y.","journal-title":"J Transl Med"},{"key":"446_CR204","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/0753-3322(94)90007-8","volume":"48","author":"Y Shirahige","year":"1994","unstructured":"Shirahige Y, Cai R-Z, Szepeshazi K, Halmos G, Pinski J, Groot K, et al. Inhibitory effect of bombesin\/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice. Biomed Pharmacother. 1994;48:465\u201372. https:\/\/doi.org\/10.1016\/0753-3322(94)90007-8.","journal-title":"Biomed Pharmacother"},{"key":"446_CR205","doi-asserted-by":"publisher","first-page":"63","DOI":"10.22270\/ajprd.v7i2.463","volume":"7","author":"S Shrivastava","year":"2019","unstructured":"Shrivastava S, Jain S, Kumar D, Soni SL, Sharma M. A review on theranostics: an approach to targeted diagnosis and therapy. Asian J Pharm Res Dev. 2019;7:63\u20139.","journal-title":"Asian J Pharm Res Dev"},{"key":"446_CR206","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3390\/jcm8050681","volume":"8","author":"A Signore","year":"2019","unstructured":"Signore A, Lauri C, Auletta S, Anzola K, Galli F, Casali M, et al. Immuno-imaging to predict treatment response in infection, inflammation and oncology. J Clin Med. 2019;8:681.","journal-title":"J Clin Med"},{"key":"446_CR207","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1093\/annonc\/mdp028","volume":"20","author":"C Simmons","year":"2009","unstructured":"Simmons C, Miller N, Geddie W. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol. 2009;20:1499\u2013504.","journal-title":"Ann Oncol"},{"key":"446_CR208","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"DJ Slamon","year":"2011","unstructured":"Slamon DJ, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273\u201383.","journal-title":"N Engl J Med"},{"key":"446_CR211","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1021\/bc020034r","volume":"14","author":"CJ Smith","year":"2003","unstructured":"Smith CJ, Gali H, Sieckman GL, Higginbotham C, Volkert WA, Hoffman TJ. Radiochemical investigations of 99mTc-N3S-X-BBN [7\u201314]-NH2: an in vitro\/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties. Bioconjug Chem. 2003c;14:93\u2013102.","journal-title":"Bioconjug Chem"},{"key":"446_CR209","first-page":"4082","volume":"63","author":"CJ Smith","year":"2003","unstructured":"Smith CJ, Sieckman GL, Owen NK, Hayes DL, Mazuru DG, Kannan R. Radiochemical investigations of gastrin-releasing peptide receptor-specific [(99m)Tc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro\/in vivo studies where Dpr = 2,3-diaminopropionic acid and X = H2O or P(CH2OH)3. Cancer Res. 2003a;63:4082\u20138.","journal-title":"Cancer Res"},{"key":"446_CR210","first-page":"125","volume":"26","author":"MC Smith","year":"2003","unstructured":"Smith MC, Orlando C, Serio M, Maggi M. Somatostatin receptors and breast cancer. J Endocrinol Investig. 2003b;26:125\u201330.","journal-title":"J Endocrinol Investig"},{"key":"446_CR215","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0932692100","author":"T Sorlie","year":"2003","unstructured":"Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003. https:\/\/doi.org\/10.1073\/pnas.0932692100.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"446_CR216","doi-asserted-by":"publisher","first-page":"6243","DOI":"10.1158\/0008-5472.CAN-06-0450","volume":"66","author":"F Souaz\u00e9","year":"2006","unstructured":"Souaz\u00e9 F, Dupouy S, Viardot-Foucault V, Bruyneel E, Attoub S, Gespach C, et al. Expression of Neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res. 2006;66:6243\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-0450.","journal-title":"Cancer Res"},{"key":"446_CR213","doi-asserted-by":"publisher","first-page":"730","DOI":"10.2967\/jnumed.113.131243","volume":"55","author":"J S\u00f6rensen","year":"2014","unstructured":"S\u00f6rensen J, Sandberg D, Sandstr\u00f6m M, Wennborg A, Feldwisch J, Tolmachev V, et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J Nucl Med. 2014b;55:730\u20135. . https:\/\/doi.org\/10.2967\/jnumed.113.131243","journal-title":"J Nucl Med"},{"key":"446_CR212","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.131243","volume":"55","author":"J S\u00f6rensen","year":"2014","unstructured":"S\u00f6rensen J, Sandberg D, Sandstr\u00f6m M, Wennborg A, Feldwisch J, Tolmachev V, et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J Nucl Med. 2014a;55:730. https:\/\/doi.org\/10.2967\/jnumed.113.131243.","journal-title":"J Nucl Med"},{"key":"446_CR214","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7150\/thno.13502","volume":"6","author":"J S\u00f6rensen","year":"2016","unstructured":"S\u00f6rensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, et al. Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 affibody PET\/CT. Theranostics. 2016;6:262\u201371. https:\/\/doi.org\/10.7150\/thno.13502.","journal-title":"Theranostics"},{"key":"446_CR217","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.7150\/thno.14958","volume":"6","author":"C Stoykow","year":"2016","unstructured":"Stoykow C, Erbes T, Maecke HR, Bulla S, Bartholom\u00e4 M, Mayer S, et al. Gastrin-releasing peptide receptor imaging in breast cancer using the receptor antagonist 68Ga-RM2 and PET. Theranostics. 2016;6:1641\u201350.","journal-title":"Theranostics"},{"key":"446_CR220","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"446_CR219","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2967\/jnumed.124.269024","volume":"66","author":"L Sun","year":"2025","unstructured":"Sun L, Sun Y, Zuo K, Fan L, Wang X, Zhang J, et al. Pilot study of Nectin-4\u2013targeted PET imaging agent 68Ga-FZ-NR-1 in triple-negative breast cancer from bench to first-in-human. J Nucl Med. 2025;66:473\u20139. . https:\/\/doi.org\/10.2967\/jnumed.124.269024","journal-title":"J Nucl Med"},{"key":"446_CR218","first-page":"242068","volume":"65","author":"Y Sun","year":"2024","unstructured":"Sun Y, Gao H, hao Z, yang g, pan b, yu y, et al. first-in-human spect imaging of trop2 in breast Cancer and tnbc patients using 99mTc-Trop2-VHH. J Nucl Med Soc Nucl Med. 2024;65:242068\u2013242068.","journal-title":"J Nucl Med Soc Nucl Med"},{"key":"446_CR221","first-page":"504","volume":"64","author":"T Suzuki","year":"2006","unstructured":"Suzuki T, Uno K, Kubo A. Usefulness of 18F-FDG PET in the diagnosis for breast cancer patients. Nihon Rinsho. 2006;64:504\u201310.","journal-title":"Nihon Rinsho"},{"key":"446_CR222","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.2967\/jnumed.112.118612","volume":"54","author":"K Tamura","year":"2013","unstructured":"Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med. 2013;54:1869\u201375. https:\/\/doi.org\/10.2967\/jnumed.112.118612.","journal-title":"J Nucl Med"},{"key":"446_CR223","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.2967\/jnumed.117.205088","volume":"59","author":"L Tang","year":"2018","unstructured":"Tang L, Peng C, Tang B, Li Z, Wang X, Li J. Radioiodinated small-molecule tyrosine kinase inhibitor for HER2-selective SPECT imaging. J Nucl Med Publ Soc Nucl Med. 2018;59:1386\u201391.","journal-title":"J Nucl Med Publ Soc Nucl Med"},{"key":"446_CR224","first-page":"373","volume":"65","author":"K Tayama","year":"2007","unstructured":"Tayama K, Toh U, Fujii T, Shirouzu K, Kaida Y. Usefulness of 18F-FDG-PET in breast cancer imaging. Nihon Rinsho. 2007;65:373\u20138.","journal-title":"Nihon Rinsho"},{"key":"446_CR225","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2967\/jnumed.112.114876","volume":"54","author":"ML Thakur","year":"2013","unstructured":"Thakur ML, Zhang K, Berger A, Cavanaugh B, Kim S, Channappa C, et al. VPAC1 receptors for imaging breast cancer: a feasibility study. J Nucl Med. 2013;54:1019\u201325. https:\/\/doi.org\/10.2967\/jnumed.112.114876.","journal-title":"J Nucl Med"},{"key":"446_CR226","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1124\/jpet.107.135723","volume":"325","author":"L Thomas","year":"2008","unstructured":"Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based Dipeptidyl Peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other Dipeptidyl Peptidase-4 inhibitorss. J Pharmacol Exp Ther. 2008;325:175\u201382. https:\/\/doi.org\/10.1124\/jpet.107.135723.","journal-title":"J Pharmacol Exp Ther"},{"key":"446_CR227","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1007\/s00330-017-4831-y","volume":"27","author":"F Tian","year":"2017","unstructured":"Tian F, Shen G, Deng Y, Diao W, Jia Z. The accuracy of 18F-FDG PET\/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review. Eur Radiol. 2017;27:4786\u201396.","journal-title":"Eur Radiol"},{"key":"446_CR228","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.2174\/092986710791859397","volume":"17","author":"V Tolmachev","year":"2010","unstructured":"Tolmachev V, Orlova A. Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets. Curr Med Chem. 2010;17:2636\u201355.","journal-title":"Curr Med Chem"},{"key":"446_CR229","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.nucmedbio.2017.04.007","volume":"51","author":"SK Tripathi","year":"2017","unstructured":"Tripathi SK, Kumar P, Trabulsi EJ, Kim S, McCue PA, Intenzo C, et al. VPAC1 targeted 64Cu-TP3805 kit preparation and its evaluation. Nucl Med Biol. 2017;51:55\u201361. https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.04.007.","journal-title":"Nucl Med Biol"},{"key":"446_CR230","doi-asserted-by":"publisher","first-page":"6572","DOI":"10.1021\/jm1002556","volume":"53","author":"T-Y Tsai","year":"2010","unstructured":"Tsai T-Y, Yeh T-K, Chen X, Hsu T, Jao Y-C, Huang C-H, et al. Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein. J Med Chem. 2010;53:6572\u201383.","journal-title":"J Med Chem"},{"key":"446_CR231","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.nucmedbio.2006.12.003","volume":"34","author":"T Tsuchida","year":"2007","unstructured":"Tsuchida T, Okazawa H, Mori T. In vivo imaging of estrogen receptor concentration in the endometrium and myometrium using FES PET\u2014influence of menstrual cycle and endogenous estrogen level. Nucl Med Biol. 2007;34:205\u201310.","journal-title":"Nucl Med Biol"},{"key":"446_CR232","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-018-0442-0","volume":"8","author":"T Vag","year":"2018","unstructured":"Vag T, Steiger K, Rossmann A, Keller U, Noske A, Herhaus P, et al. PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma. EJNMMI Res. 2018;8:90. https:\/\/doi.org\/10.1186\/s13550-018-0442-0.","journal-title":"EJNMMI Res"},{"issue":"11","key":"446_CR233","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1007\/s00259-015-3107-5","volume":"42","author":"M vanKruchten","year":"2015","unstructured":"vanKruchten M, Glaudemans AW, de Vries EF, Schr\u00f6der CP, de Vries EG, Hospers GA. Positron emission tomography of tumour [18F] fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy. Eur J Nucl Med Mol Imaging. 2015;42(11):1674\u201381.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"446_CR234","doi-asserted-by":"publisher","first-page":"10455","DOI":"10.3390\/molecules190710455","volume":"19","author":"Z Varasteh","year":"2014","unstructured":"Varasteh Z, Rosenstr\u00f6m U, Velikyan I, Mitran B, Altai M, Honarvar H, et al. The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin. Molecules. 2014;19:10455\u201372.","journal-title":"Molecules"},{"key":"446_CR235","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.nucmedbio.2013.07.004","volume":"40","author":"K Varmira","year":"2013","unstructured":"Varmira K, Hosseinimehr SJ, Noaparast Z, Abedi SM. A HER2-targeted RNA aptamer molecule labeled with 99mTc for single-photon imaging in malignant tumors. Nucl Med Biol. 2013;40:980\u20136.","journal-title":"Nucl Med Biol"},{"key":"446_CR236","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3109\/1061186X.2013.839688","volume":"22","author":"K Varmira","year":"2014","unstructured":"Varmira K, Hosseinimehr SJ, Noaparast Z, Abedi SM. An improved radiolabelled RNA aptamer molecule for HER2 imaging in cancers. J Drug Target. 2014;22:116\u201322.","journal-title":"J Drug Target"},{"key":"446_CR237","first-page":"12","volume":"9","author":"I Velikyan","year":"2019","unstructured":"Velikyan I, Schweigh\u00f6fer P, Feldwisch J, Seemann J, Frejd FY, Lindman H. Diagnostic HER2-binding radiopharmaceutical, [68Ga] Ga-ABY-025, for routine clinical use in breast cancer patients. Am J Nucl Med Mol Imaging. 2019;9:12\u201323.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"446_CR238","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/RLU.0000000000001347","volume":"41","author":"CM Venema","year":"2016","unstructured":"Venema CM, Apollonio G, Hospers GAP, Schr\u00f6der CP, Dierckx RAJO, Vries EFJ. Recommendations and technical aspects of 16\u03b1-[18F]Fluoro-17\u03b2-Estradiol PET to image the estrogen receptor in vivo. Clin Nucl Med. 2016;41:844\u201351. . https:\/\/doi.org\/10.1097\/RLU.0000000000001347","journal-title":"Clin Nucl Med"},{"key":"446_CR239","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1200\/JCO.2007.11.9453","volume":"25","author":"G Viale","year":"2007","unstructured":"Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell\u2019Orto P, Rasmussen BB. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25:3846\u201352.","journal-title":"J Clin Oncol"},{"key":"446_CR240","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1021\/jo020190r","volume":"67","author":"D Vijaykumar","year":"2002","unstructured":"Vijaykumar D, Mao W, Kirschbaum KS, Katzenellenbogen JA. An efficient route for the preparation of a 21-fluoro progestin-16\u03b1,17\u03b1-dioxolane, a high-affinity ligand for PET imaging of the progesterone receptor. J Org Chem. 2002;67:4904\u201310. https:\/\/doi.org\/10.1021\/jo020190r.","journal-title":"J Org Chem"},{"key":"446_CR241","first-page":"13","volume":"47","author":"HN Wagner Jr","year":"2006","unstructured":"Wagner HN Jr. From molecular imaging to molecular medicine. J Nucl Med Publ Soc Nucl Med. 2006;47:13\u201339.","journal-title":"J Nucl Med Publ Soc Nucl Med."},{"key":"446_CR244","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176129","volume":"960","author":"H Wang","year":"2023","unstructured":"Wang H, Sun D, Chen J, Li H, Chen L. Nectin-4 has emerged as a compelling target for breast cancer. Eur J Pharmacol. 2023;960:176129. https:\/\/doi.org\/10.1016\/j.ejphar.2023.176129.","journal-title":"Eur J Pharmacol"},{"key":"446_CR242","doi-asserted-by":"publisher","first-page":"15695","DOI":"10.1016\/S0021-9258(18)55454-5","volume":"265","author":"LH Wang","year":"1990","unstructured":"Wang LH, Coy DH, Taylor JE, Jiang NY, Moreau JP, Huang SC, et al. Des-Met carboxyl-terminally modified analogues of bombesin function as potent bombesin receptor antagonists, partial agonists, or agonists. J Biol Chem. 1990;265:15695\u2013703.","journal-title":"J Biol Chem"},{"key":"446_CR245","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103838","volume":"79","author":"Y Wang","year":"2025","unstructured":"Wang Y, Li G, Wang H, Qi Q, Wang X, Lu H. Targeted therapeutic strategies for Nectin-4 in breast cancer: recent advances and future prospects. Breast. 2025;79:103838. https:\/\/doi.org\/10.1016\/j.breast.2024.103838.","journal-title":"Breast"},{"issue":"45","key":"446_CR243","doi-asserted-by":"publisher","first-page":"190548","DOI":"10.1002\/adfm.201905480","volume":"29","author":"Z Wang","year":"2019","unstructured":"Wang Z, Ma Y, Wang H, Wang F, Xu T, Gu Y. CXCR4-Enriched nano-trap targeting CXCL12 in lung for early prevention and enhanced photodynamic therapy of breast cancer metastasis. Adv Funct Mater. 2019;29(45):190548.","journal-title":"Adv Funct Mater."},{"key":"446_CR246","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1007\/s002590000355","volume":"27","author":"C Wiele","year":"2000","unstructured":"Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W, Cocquyt V, Serreyn R, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med. 2000;27:1694\u20139.","journal-title":"Eur J Nucl Med"},{"key":"446_CR247","doi-asserted-by":"publisher","first-page":"412","DOI":"10.7150\/thno.7324","volume":"4","author":"G Wieser","year":"2014","unstructured":"Wieser G, Mansi R, Grosu AL, Schultze-Seemann W, Dumont-Walter RA, Meyer PT, et al. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist\u2014From mice to men. Theranostics. 2014;4:412\u20139.","journal-title":"Theranostics"},{"key":"446_CR249","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1007\/s00259-020-04754-6","volume":"47","author":"Y Wu","year":"2020","unstructured":"Wu Y, Li L, Wang Z, Shi J, Hu Z, Gao S, et al. Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe 99mTc-HYNIC-H10F. Eur J Nucl Med Mol Imaging. 2020;47:2613\u201323. . https:\/\/doi.org\/10.1007\/s00259-020-04754-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"446_CR250","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-023-00235-x","volume":"9","author":"Y Wu","year":"2024","unstructured":"Wu Y, Li T, Zhang X, Jing H, Li F, Huo L. Preclinical evaluation of the theranostic potential of (89)Zr\/(177)Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model. EJNMMI Radiopharm Chem. 2024;9:5. https:\/\/doi.org\/10.1186\/s41181-023-00235-x.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"446_CR248","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.2967\/jnumed.114.137489","volume":"55","author":"Z Wu","year":"2014","unstructured":"Wu Z, Li L, Liu S, Yakushijin F, Yakushijin K, Horne D, et al. Facile preparation of a thiol-reactive 18F-labeling agent and synthesis of 18F-DEG-VS-NT for PET imaging of a neurotensin receptor\u2013positive tumor. J Nucl Med. 2014;55:1178\u201384. . https:\/\/doi.org\/10.2967\/jnumed.114.137489","journal-title":"J Nucl Med"},{"key":"446_CR251","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201800382","author":"C Xu","year":"2018","unstructured":"Xu C, Feng Q, Yang H, Wang G, Huang L, Bai Q, et al. A light-triggered mesenchymal stem cell delivery system for photoacoustic imaging and chemo-photothermal therapy of triple negative breast cancer. Adv Sci. 2018. https:\/\/doi.org\/10.1002\/advs.201800382.","journal-title":"Adv Sci"},{"key":"446_CR252","doi-asserted-by":"publisher","first-page":"220","DOI":"10.7150\/thno\/v01p0220","volume":"1","author":"M Yang","year":"2012","unstructured":"Yang M, Gao H, Zhou Y, Ma Y, Quan Q, Lang L. 18F-labeled GRPR agonists and antagonists: a comparative study in prostate cancer imaging. Theranostics. 2012;1:220\u20139. . https:\/\/doi.org\/10.7150\/thno\/v01p0220","journal-title":"Theranostics"},{"key":"446_CR253","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1292211","volume":"13","author":"L Yao","year":"2023","unstructured":"Yao L, Chen J, Ma W. Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements. Front Oncol. 2023;13:1292211. https:\/\/doi.org\/10.3389\/fonc.2023.1292211.","journal-title":"Front Oncol"},{"key":"446_CR254","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28124707","volume":"28","author":"J Yu","year":"2023","unstructured":"Yu J, Zhou X, Shen L. CXCR4-targeted radiopharmaceuticals for the imaging and therapy of malignant tumors. Molecules. 2023;28:4707. https:\/\/doi.org\/10.3390\/molecules28124707.","journal-title":"Molecules"},{"key":"446_CR255","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/RLU.0000000000002209","volume":"43","author":"J Zang","year":"2018","unstructured":"Zang J, Mao F, Wang H, Zhang J, Liu Q, Peng L, et al. 68Ga-NOTA-RM26 PET\/CT in the evaluation of breast cancer: a pilot prospective study. Clin Nucl Med. 2018;43:663\u20139.","journal-title":"Clin Nucl Med"},{"key":"446_CR256","doi-asserted-by":"publisher","first-page":"922","DOI":"10.2967\/jnumed.117.198929","volume":"59","author":"J Zhang","year":"2018","unstructured":"Zhang J, Niu G, Fan X, Lang L, Hou G, Chen L, et al. PET using a GRPR antagonist 68Ga-RM26 in healthy volunteers and prostate cancer patients. J Nucl Med. 2018;59:922\u20138.","journal-title":"J Nucl Med"},{"key":"446_CR257","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1158\/0008-5472.CAN-16-1945","volume":"77","author":"R Zhou","year":"2016","unstructured":"Zhou R, Pantel AR, Li S, Lieberman BP, Ploessl K, Choi H. (2S,4R)4-fluoroglutamine PET detects glutamine pool size changes in triple-negative breast cancer in response to glutaminase inhibition. Cancer Res. 2016;77:1476\u201384. . https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1945","journal-title":"Cancer Res."}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-026-00446-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00446-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00446-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T01:04:02Z","timestamp":1781226242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41181-026-00446-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,26]]},"references-count":257,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["446"],"URL":"https:\/\/doi.org\/10.1186\/s41181-026-00446-y","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,26]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval not applicable to this article as no new research involving human or animal subjects was performed for this review paper. Consent to participate not applicable to this article as no new research involving human subjects was performed for this review paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent to publish not applicable to this article as no new research involving human subjects was performed for this review paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"P. Para\u00efso and Y. Seimbille declare that they have no financial interests to disclose. C.H.M. van Deurzen has received support from a pharmaceutical, device or biotechnology company (Roche and Aztrazeneca).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}